

08-27-06

JFw


UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: YU et al. Examiner: UNKNOWN
Serial No.: 10/584877 ✓ Group Art: UNKNOWN
Filed: June 29, 2006 Docket: 09548.1035USWO
Title: THERAPEUTIC DRUGS FOR ARTHRITIS

CERTIFICATE UNDER 37 CFR 1.10

Express Mail mailing label number: EV 858800576 US
Date of Deposit: August 18, 2006

I hereby certify that the papers listed below are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: 

Name: RAYANN WILHELM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The following papers are transmitted herewith:

- Transmittal Sheet in duplicate containing Certificate of Mailing
- Information Disclosure Statement, Form 1449, 8 references
- Form PCT/IB/304
- Return Postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. A duplicate of this sheet is enclosed.

Hamre, Schumann, Mueller & Larson, P.C.
P.O. Box 2902 Minneapolis, MN 55402
612.455-3800

By: 

Name: Michael D. Schumann
Reg. No.: 30,422
Initials: MDS:rkw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: YU et al. Examiner: Unknown
Serial No.: 10/584877 Group Art Unit: Unknown
Filed: June 29, 2006 Docket: 09548.1035USWO
Title: THERAPEUTIC DRUGS FOR ARTHRITIS

CERTIFICATE UNDER 37 CFR 1.10

Express Mail mailing label number: EV 858800576 US

Date of Deposit: August 18, 2006

I hereby certify that the papers listed below are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: 

Name: RALYNN WILHELM

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. Copies of any foreign patent documents or "Other Documents" are enclosed.

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the Filing Date, before the mailing date of a First Office Action on the merits, or before the mailing date of a First Office Action on the merits after the filing of a request for continued examination under 37 C.F.R. §1.114; or
- (2) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and
- the requisite Statement is below, OR
- the requisite fee of \$180.00 under Rule 1.17(p) is included herein, or

- (3) after the mailing date of a Final Rejection or Notice of Allowance but on or before the payment of the Issue Fee, AND
- the requisite Statement is below, AND
- the requisite fee of \$180.00 under Rule 1.17(p) is included herein.

STATEMENT

As required under §1.97(e), Applicants hereby state either that:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or
 - 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
- If this box is checked, Applicant provides the following:

Certification Under 37 C.F.R. §1.704(d)

In accordance with 37 C.F.R. §1.704(d), the undersigned hereby certifies that each item listed on the enclosed Form 1449 was first cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

- The Examiner is hereby advised of the following co-pending U.S. applications. A copy of each U.S. patent application publication (if published) or application (if not published) is enclosed.

Application No.

Filing Date

Group

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached

Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

FEE AUTHORIZATION

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 50-3478. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &
LARSON, P.C.
Post Office Box 2902
Minneapolis, MN 55402-0902
(612) 455-3800

Dated: August 18, 2006

By:


Michael D. Schumann
Reg. No. 30,422

MDS:rkw

FORM 1449* O I P E INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(Use several sheets if necessary)</small>			Docket Number: 09548.1035USWO	Application Number: 10/584,877
			Applicant: YU et al.	
			Filing Date: June 29, 2006	Group Art Unit Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 6,552,071	04/2003	Yuan et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Bhargava KK. et al., "Isolation of Desmethylwedelolactone and its Glucoside from <i>Eclipta alba</i> ", INDIAN J. CHEM., 1970, Vol. 8, No. 7, pp. 664-665.				
		Melo et al., "Inhibition of the Myotoxic and Hemorrhagic Activities of Crotalid Venoms by <i>Eclipta Prostrata</i> (Asteraceae) Extracts and Constituents", TOXICON, May 1994, Vol. 32, No. 5, pp. 595-603.				
		Govindachari et al., "Chemical Examination of Wedelia calendulacea, Part I, Structure of Wedelolactone." JOURNAL OF THE CHEMICAL SOCIETY, 1956, pp. 629-632.				
		Govindachari et al., "Chemical Investigation of Wedelia calendulacea, Part II, the Position of the Methoxyl Group in Wedelolactone." JOURNAL OF THE CHEMICAL SOCIETY, 1957, pp. 545-547.				
		Li CC. et al., "Total Synthesis of Wedelolactone", J ORG CHEM., October 31, 2003, Vol. 68, No. 22, pp. 8500-8504.				
		Wong S.M. et al., "Wedelolactone and Coumestan Derivatives as New Antihepatotoxic and Antiphlogistic Principles," ARZNEIMITTELFORSHUNG., May 1998, Vol. 38, No. 5, pp. 661-665.				
		Arend, William P., "The Pathophysiology and Treatment of rheumatoid Arthritis," ARTHRITIS & RHEUMATISM, April 1997, Vol. 40, No. 4, pp. 595-597.				
		Li, KJ. et al., "Anti-rheumatoid arthritis drugs developed in recent years" The international medicine antibiotics chapter. 2003; Jan. 24 (1); 24-29 - ABSTRACT				



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	